Unlock instant, AI-driven research and patent intelligence for your innovation.

ShRNA targeting MED23 for treating liver cancer and application of shRNA

A targeted technology for the treatment of liver cancer, applied in the field of biomedicine, can solve problems such as unsatisfactory curative effect

Active Publication Date: 2021-08-27
FUDAN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For advanced liver cancer, the curative effect of the currently approved first-line target drugs Sorafenib (Sorafenib) and Lenvatinib (Lenvatinib) is not satisfactory, and can only prolong the life of patients by 3-5 months

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ShRNA targeting MED23 for treating liver cancer and application of shRNA
  • ShRNA targeting MED23 for treating liver cancer and application of shRNA
  • ShRNA targeting MED23 for treating liver cancer and application of shRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0038] In order to make the purpose, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the implementation of the present invention. example, not all examples. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.

[0039] Transcription mediator (Mediator), as a bridge for information transmission, connects transcription factors, general transcription factors and Pol II, and generally participates in the transcription process of genes regulated by Pol II. The classic function of Mediator is to help recruit and stabilize the transcription initiation complex (pre-initiation-complex, PI...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides shRNA targeting MED23 for treating liver cancer and an application of the shRNA. The invention provides shRNA targeting MED23 for treating liver cancer on the first aspect, wherein the shRNA has a sequence as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The shRNA provided by the invention can knock down the expression quantity of MED23 in vivo, can be directly used as a basis for siRNA drug design, and is used for preventing and treating liver cancer.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a shRNA targeting MED23 for treating liver cancer and its application, and a drug for treating liver cancer. Background technique [0002] Liver cancer (hepatocellular carcinoma, HCC) is the seventh most common malignant tumor in the world, but its mortality rate ranks third, second only to lung cancer and gastric cancer. The morbidity and mortality of liver cancer in China rank first, and more than 50% of the new cases and deaths in the world every year occur in China, which brings a great burden to the health of our country. [0003] At present, the treatment of liver cancer is mainly based on the diagnosis and corresponding treatment of patients based on the Barcelona grading standard. For advanced liver cancer, the curative effect of the currently approved first-line target drugs Sorafenib (Sorafenib) and Lenvatinib (Lenvatinib) is not satisfactory, and can only prolong ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K31/7088A61P1/16A61P35/00
CPCC12N15/1135A61K31/7088A61P1/16A61P35/00Y02A50/30
Inventor 王纲王智超
Owner FUDAN UNIV